Jane Street Group LLC Decreases Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Jane Street Group LLC lessened its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 74.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,390 shares of the medical device company's stock after selling 66,943 shares during the period. Jane Street Group LLC's holdings in AtriCure were worth $628,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ATRC. Champlain Investment Partners LLC boosted its position in AtriCure by 4.3% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company's stock worth $78,253,000 after buying an additional 115,813 shares during the period. First Light Asset Management LLC raised its position in AtriCure by 42.1% during the 2nd quarter. First Light Asset Management LLC now owns 1,964,703 shares of the medical device company's stock worth $44,736,000 after purchasing an additional 581,843 shares during the last quarter. Hood River Capital Management LLC bought a new stake in shares of AtriCure in the 2nd quarter valued at about $40,422,000. Wellington Management Group LLP grew its position in shares of AtriCure by 0.4% in the 3rd quarter. Wellington Management Group LLP now owns 1,543,896 shares of the medical device company's stock valued at $43,291,000 after buying an additional 6,045 shares during the last quarter. Finally, State Street Corp increased its stake in shares of AtriCure by 4.9% in the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock valued at $37,710,000 after buying an additional 63,002 shares during the period. Institutional investors and hedge funds own 99.11% of the company's stock.

Wall Street Analysts Forecast Growth

ATRC has been the topic of several analyst reports. Oppenheimer upped their target price on AtriCure from $32.00 to $36.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Canaccord Genuity Group increased their price target on AtriCure from $53.00 to $61.00 and gave the stock a "buy" rating in a report on Monday, December 9th. StockNews.com upgraded shares of AtriCure from a "sell" rating to a "hold" rating in a research note on Saturday, September 14th. UBS Group raised their price target on shares of AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. Finally, Needham & Company LLC upped their price objective on shares of AtriCure from $34.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $42.00.

AtriCure Stock Up 5.4 %

Shares of AtriCure stock traded up $1.63 during trading hours on Friday, reaching $32.03. The company's stock had a trading volume of 440,541 shares, compared to its average volume of 389,570. The company has a market capitalization of $1.56 billion, a P/E ratio of -38.59 and a beta of 1.42. The stock's fifty day simple moving average is $33.71 and its two-hundred day simple moving average is $28.14. AtriCure, Inc. has a one year low of $18.94 and a one year high of $39.04. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02. The firm had revenue of $115.91 million during the quarter, compared to the consensus estimate of $112.23 million. AtriCure had a negative return on equity of 8.12% and a negative net margin of 8.70%. The company's quarterly revenue was up 17.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.20) earnings per share. On average, research analysts forecast that AtriCure, Inc. will post -0.72 earnings per share for the current year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.